$EQ
Equillium, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023040583 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $8.870M $9.124M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.520M $3.105M $4.064M
YoY Change -21.18% -23.6% 42.2%
% of Gross Profit
Research & Development $8.974M $9.610M $9.488M
YoY Change 2.31% 1.29% 58.53%
% of Gross Profit
Depreciation & Amortization $30.00K $31.00K $31.00K
YoY Change 0.0% 0.0% 121.43%
% of Gross Profit
Operating Expenses $12.49M $12.72M $13.55M
YoY Change -5.62% -6.18% 53.25%
Operating Profit -$3.623M -$3.591M -$13.55M
YoY Change -72.63% -73.5% 53.25%
Interest Expense $550.0K $368.0K -$195.0K
YoY Change -501.46% -288.72% -24.12%
% of Operating Profit
Other Income/Expense, Net -$142.0K -$112.0K -$577.0K
YoY Change -66.03% -80.59% 83.17%
Pretax Income -$3.214M -$3.335M -$14.13M
YoY Change -76.46% -76.4% 54.28%
Income Tax $500.0K $8.000K $0.00
% Of Pretax Income
Net Earnings -$3.710M -$3.343M -$14.13M
YoY Change -72.83% -76.34% 54.28%
Net Earnings / Revenue -41.83% -36.64%
Basic Earnings Per Share -$0.11 -$0.10 -$0.41
Diluted Earnings Per Share -$0.11 -$0.10 -$0.41
COMMON SHARES
Basic Shares Outstanding 34.57M 34.41M 34.29M
Diluted Shares Outstanding 34.88M 34.45M 34.29M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.31M $48.38M $57.56M
YoY Change 4.01% -15.95% -41.05%
Cash & Equivalents $34.38M $25.62M $23.81M
Short-Term Investments $11.92M $22.75M $33.75M
Other Short-Term Assets $3.800M $5.235M $2.920M
YoY Change 68.59% 79.28% 51.85%
Inventory
Prepaid Expenses
Receivables $3.800M $3.700M
Other Receivables $0.00 $0.00
Total Short-Term Assets $53.91M $57.36M $60.48M
YoY Change 15.25% -5.17% -39.25%
LONG-TERM ASSETS
Property, Plant & Equipment $313.0K $329.0K $451.0K
YoY Change -26.0% -27.05% 77.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $79.00K $87.00K $121.0K
YoY Change -30.09% -28.1% 611.76%
Total Long-Term Assets $1.314M $1.408M $1.990M
YoY Change -29.16% -29.25% 634.32%
TOTAL ASSETS
Total Short-Term Assets $53.91M $57.36M $60.48M
Total Long-Term Assets $1.314M $1.408M $1.990M
Total Assets $55.23M $58.76M $62.47M
YoY Change 13.56% -5.94% -37.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.635M $3.026M $5.091M
YoY Change 47.23% -40.56% 180.34%
Accrued Expenses $8.304M $7.537M $5.377M
YoY Change 31.27% 40.17% 69.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $4.286M
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $28.20M $25.22M $15.19M
YoY Change 88.87% 66.04% 204.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $5.992M
YoY Change -100.0% -100.0% -40.48%
Other Long-Term Liabilities $2.900M $6.565M $1.025M
YoY Change 213.51% 540.49% 5929.41%
Total Long-Term Liabilities $2.900M $6.565M $5.992M
YoY Change -37.18% 9.56% -40.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.20M $25.22M $15.19M
Total Long-Term Liabilities $2.900M $6.565M $5.992M
Total Liabilities $31.12M $31.78M $22.21M
YoY Change 52.01% 43.13% 47.4%
SHAREHOLDERS EQUITY
Retained Earnings -$183.4M -$179.7M -$161.5M
YoY Change 4.69% 11.25% 81.34%
Common Stock $207.0M $206.3M $201.9M
YoY Change 1.92% 2.17% 16.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.11M $26.98M $40.27M
YoY Change
Total Liabilities & Shareholders Equity $55.23M $58.76M $62.47M
YoY Change 13.56% -5.94% -37.43%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$3.710M -$3.343M -$14.13M
YoY Change -72.83% -76.34% 54.28%
Depreciation, Depletion And Amortization $30.00K $31.00K $31.00K
YoY Change 0.0% 0.0% 121.43%
Cash From Operating Activities -$1.910M -$6.215M -$11.26M
YoY Change -85.38% -44.8% 60.89%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $0.00 -$54.00K
YoY Change -100.0% 134.78%
Acquisitions
YoY Change
Other Investing Activities $11.00M $15.00M $8.745M
YoY Change -26.67% 71.53% -69.83%
Cash From Investing Activities $10.98M $15.00M $8.691M
YoY Change -26.8% 72.59% -70.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -260.0K -7.618M 141.0K
YoY Change -5502.84% -79.91%
NET CHANGE
Cash From Operating Activities -1.910M -6.215M -11.26M
Cash From Investing Activities 10.98M 15.00M 8.691M
Cash From Financing Activities -260.0K -7.618M 141.0K
Net Change In Cash 8.810M 1.167M -2.427M
YoY Change 355.3% -148.08% -110.71%
FREE CASH FLOW
Cash From Operating Activities -$1.910M -$6.215M -$11.26M
Capital Expenditures $20.00K $0.00 -$54.00K
Free Cash Flow -$1.930M -$6.215M -$11.21M
YoY Change -85.23% -44.53% 60.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001746466
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
eq Research And Experimental Expenditures Capitalized Cost Amortization Period
ResearchAndExperimentalExpendituresCapitalizedCostAmortizationPeriod
P5Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38692
dei Entity Registrant Name
EntityRegistrantName
EQUILLIUM, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1554746
dei Entity Address Address Line1
EntityAddressAddressLine1
2223 Avenida de la Playa
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
412-5302
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
EQ
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34568500
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25624000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59107000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
22754000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
11916000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3743000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2838000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5235000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2874000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
57356000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
76735000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
992000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1191000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
329000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
391000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
87000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104000
CY2023Q2 us-gaap Assets
Assets
58764000
CY2022Q4 us-gaap Assets
Assets
78421000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3026000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3977000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7537000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7239000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14239000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14700000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5714000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
416000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
408000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
25218000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32038000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3239000
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5956000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10378000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
609000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
824000
CY2023Q2 us-gaap Liabilities
Liabilities
31783000
CY2022Q4 us-gaap Liabilities
Liabilities
46479000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34568500
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34568500
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34414149
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34414149
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
206326000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
204268000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
340000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
76000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179688000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172405000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
26981000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31942000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58764000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78421000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9124000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18003000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9610000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9488000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
18882000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20251000
eq Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
23049000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3105000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4064000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6820000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7581000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
12715000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
13552000
us-gaap Operating Expenses
OperatingExpenses
25702000
us-gaap Operating Expenses
OperatingExpenses
50881000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3591000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13552000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7699000
us-gaap Operating Income Loss
OperatingIncomeLoss
-50881000
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
259000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
259000
us-gaap Interest Expense Debt
InterestExpenseDebt
491000
us-gaap Interest Expense Debt
InterestExpenseDebt
515000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
627000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
64000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1266000
us-gaap Investment Income Interest
InvestmentIncomeInterest
90000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-112000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-382000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-291000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-240000
CY2023Q2 eq Other Income Expense Net
OtherIncomeExpenseNet
256000
CY2022Q2 eq Other Income Expense Net
OtherIncomeExpenseNet
-577000
eq Other Income Expense Net
OtherIncomeExpenseNet
484000
eq Other Income Expense Net
OtherIncomeExpenseNet
-665000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3335000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14129000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7215000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51546000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
68000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3343000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14129000
us-gaap Net Income Loss
NetIncomeLoss
-7283000
us-gaap Net Income Loss
NetIncomeLoss
-51546000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-36000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-54000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
59000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-234000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
71000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
359000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
205000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
223000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
35000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
305000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
264000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3308000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13824000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7019000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51557000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34449769
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34449769
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34292642
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34292642
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34432057
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34432057
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33085917
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33085917
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
66505000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1298000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-316000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37417000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
52630000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
141000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1302000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
305000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14129000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40267000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31942000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1038000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
229000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3940000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
29269000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
86000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
934000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
35000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3343000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
26981000
us-gaap Profit Loss
ProfitLoss
-7283000
us-gaap Profit Loss
ProfitLoss
-51546000
eq Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
23049000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
62000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
56000
us-gaap Share Based Compensation
ShareBasedCompensation
1972000
us-gaap Share Based Compensation
ShareBasedCompensation
2600000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-270000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-245000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
180000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
100000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
597000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-73000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4882000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
905000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2421000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
220000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-930000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3623000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
332000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1447000
eq Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
8000
eq Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
-74000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14210000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23393000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
277000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
37181000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
14962000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
27000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
11245000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
700000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10181000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3294000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
9133000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
86000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
141000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-9047000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
141000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-45000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-12000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33483000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26558000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
59107000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50366000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25624000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23808000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
23049000
us-gaap Stock Issued1
StockIssued1
22542000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
507000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-03-16
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
48400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. Significant estimates in the Company’s condensed consolidated financial statements relate to accrued research and development expense, expected refunds from the Australian Taxation Office for eligible research and development activities, revenue recognition and the valuation of equity awards. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Off-Balance Sheet Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in which the majority of deposits are in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company’s investment policy includes guidelines for the quality of the related institutions and financial instruments and defines allowable investments that the Company may invest in, which the Company believes minimizes the exposure to concentration of credit risk.</span></p>
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3700000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2800000
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6669966
CY2023Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
22754000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
11916000
CY2022Q4 us-gaap Notes Payable
NotesPayable
9000000
CY2023Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
eq Prepaid And Other Current Assets Tax Incentive
PrepaidAndOtherCurrentAssetsTaxIncentive
2200000
CY2022 eq Prepaid And Other Current Assets Tax Incentive
PrepaidAndOtherCurrentAssetsTaxIncentive
1000000
eq Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
eq Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8683340
CY2022Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22784000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
31000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
22754000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
12006000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
90000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
11916000
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2023Q2 eq Accrued Clinical Development
AccruedClinicalDevelopment
4397000
CY2022Q4 eq Accrued Clinical Development
AccruedClinicalDevelopment
3253000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1841000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2975000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
661000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
472000
CY2023Q2 eq Accrued Non Clinical Research
AccruedNonClinicalResearch
638000
CY2022Q4 eq Accrued Non Clinical Research
AccruedNonClinicalResearch
465000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
74000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7537000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7239000
CY2019Q3 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2024-06-01
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
992000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
416000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
609000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1025000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M1D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
us-gaap Operating Lease Payments
OperatingLeasePayments
260000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
240000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
492000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
219000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
169000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
28000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1148000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
123000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1025000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34568500
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34414149
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M13D
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
934000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1302000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1972000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2600000
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10088567
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8178936
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
68000
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0024
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0094
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0000950170-23-040583-index-headers.html Edgar Link pending
0000950170-23-040583-index.html Edgar Link pending
0000950170-23-040583.txt Edgar Link pending
0000950170-23-040583-xbrl.zip Edgar Link pending
eq-20230630.htm Edgar Link pending
eq-20230630.xsd Edgar Link pending
eq-ex10_1.htm Edgar Link pending
eq-ex10_2.htm Edgar Link pending
eq-ex31_1.htm Edgar Link pending
eq-ex31_2.htm Edgar Link pending
eq-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
eq-20230630_def.xml Edgar Link unprocessable
eq-20230630_lab.xml Edgar Link unprocessable
eq-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
eq-20230630_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
eq-20230630_cal.xml Edgar Link unprocessable